Funding success for drug discovery spinout

A University of Southampton company that exploits groundbreaking research at the School of Chemistry and Chemical Engineering is going from strength to strength, having received substantial financing to advance and expand its work.

Curve Therapeutics, which is pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, has raised £40.5 million in Series A financing.

Curve’s powerful Microcycle® platform enables the direct discovery of biologically active molecules against targets that have been difficult to address using conventional drug discovery methods.

Ali Tavassoli, Professor of Chemical Biology and Curve’s Chief Scientific Officer, developed the technology behind Curve’s platform at the School of Chemistry and Chemical Engineering.

He says: “We look forward to maximising the potential of our platform to further develop a rich pipeline of programmes with the potential to treat unmet clinical needs in a diverse range of diseases, including cancer.”